GSK share price slips as hepatitis B drug headline leaves investors wanting the numbers
GSK shares fell 0.9% to 1,883.5 pence after late-stage hepatitis B trial results lacked detailed cure-rate data. The company reported European approval for new Shingrix packaging and Japanese approval for depemokimab. Investors await full bepirovirsen data and upcoming events, including the JPMorgan Healthcare Conference on Jan. 13.